VectorY Therapeutics Appoints Jim Scibetta as CEO and Expands U.S. Presence

Amsterdam, Netherlands and Boston, MA, December 20, 2024 (Business Wire) -- VectorY Therapeutics has appointed Jim Scibetta as its new CEO, following the transition of founder and former CEO Sander van Deventer to President of R&D. Van Deventer will continue leading the development of the company’s pipeline, including the IND-enabling studies for its lead program, VTx-002, a novel vectorized antibody targeting TDP-43 for ALS. As part of its expansion, the company has also opened a new office in Boston to strengthen its U.S. presence and support future growth.

Read full article here.